These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 17428299

  • 21. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 22. Botulinum toxin type A (BOTOX) for treatment of migraine.
    Binder WJ, Brin MF, Blitzer A, Pogoda JM.
    Semin Cutan Med Surg; 2001 Jun; 20(2):93-100. PubMed ID: 11474749
    [Abstract] [Full Text] [Related]

  • 23. Botulinum toxin as preventive treatment for migraine: a randomized double-blind study.
    Petri S, Tölle T, Straube A, Pfaffenrath V, Stefenelli U, Ceballos-Baumann A, Dysport Migraine Study Group.
    Eur Neurol; 2009 Jun; 62(4):204-11. PubMed ID: 19622887
    [Abstract] [Full Text] [Related]

  • 24. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
    Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S, Global Dysport Cervical Dystonia Study Group.
    Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
    Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL.
    Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
    [Abstract] [Full Text] [Related]

  • 26. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
    Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG.
    Mov Disord; 2006 May; 21(5):704-7. PubMed ID: 16440332
    [Abstract] [Full Text] [Related]

  • 27. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study.
    Schulte-Mattler WJ, Krack P, BoNTTH Study Group.
    Pain; 2004 May; 109(1-2):110-4. PubMed ID: 15082132
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.
    Sahai A, Khan MS, Dasgupta P.
    J Urol; 2007 Jun; 177(6):2231-6. PubMed ID: 17509328
    [Abstract] [Full Text] [Related]

  • 29. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment.
    Rubin MG, Dover J, Glogau RG, Goldberg DJ, Goldman MP, Schlessinger J.
    J Drugs Dermatol; 2009 May; 8(5):439-44. PubMed ID: 19537366
    [Abstract] [Full Text] [Related]

  • 30. Novel topical BoNTA (CosmeTox, toxin type A) cream used to treat hyperfunctional wrinkles of the face, mouth, and neck.
    Chajchir I, Modi P, Chajchir A.
    Aesthetic Plast Surg; 2008 Sep; 32(5):715-22; discussion 723. PubMed ID: 18491179
    [Abstract] [Full Text] [Related]

  • 31. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.
    Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG, Tonabersat TON-01-05 Study Group.
    Cephalalgia; 2009 Jul; 29(7):742-50. PubMed ID: 19222510
    [Abstract] [Full Text] [Related]

  • 32. Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum toxin for migraine.
    Schwedt TJ, Hentz JG, Dodick DW.
    Cephalalgia; 2007 Jun; 27(6):528-34. PubMed ID: 17459081
    [Abstract] [Full Text] [Related]

  • 33. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.
    Naumann M, Lowe NJ, Kumar CR, Hamm H, Hyperhidrosis Clinical Investigators Group.
    Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503
    [Abstract] [Full Text] [Related]

  • 34. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.
    Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL.
    Eur Urol; 2007 Sep; 52(3):850-8. PubMed ID: 17467889
    [Abstract] [Full Text] [Related]

  • 35. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC, BoNTA-039 Study Group.
    Mayo Clin Proc; 2005 Sep; 80(9):1126-37. PubMed ID: 16178492
    [Abstract] [Full Text] [Related]

  • 36. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.
    Monheit G, Carruthers A, Brandt F, Rand R.
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S51-9. PubMed ID: 17241415
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study.
    Ascher B, Rzany BJ, Grover R.
    Dermatol Surg; 2009 Oct; 35(10):1478-86. PubMed ID: 19686365
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study.
    Göbel H, Heinze A, Reichel G, Hefter H, Benecke R, Dysport myofascial pain study group.
    Pain; 2006 Nov; 125(1-2):82-8. PubMed ID: 16750294
    [Abstract] [Full Text] [Related]

  • 39. Botulinum neurotoxin-A for treatment of refractory neck pain: a randomized, double-blind study.
    Miller D, Richardson D, Eisa M, Bajwa RJ, Jabbari B.
    Pain Med; 2009 Sep; 10(6):1012-7. PubMed ID: 19594841
    [Abstract] [Full Text] [Related]

  • 40. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, BOTOX CDH Study Group.
    Headache; 2005 Apr; 45(4):293-307. PubMed ID: 15836565
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.